{"ok":true,"nota":{"id":"e7a4baed187642ae","slug":"un-modelo-sugiere-que-un-farmaco-contra-el-cancer-de-mama-seria-mas-ut-e7a4ba","titulo":"Un modelo sugiere que un fármaco contra el cáncer de mama sería más útil en casos de mayor riesgo","resumen":"Compararon dos tratamientos para cáncer de mama HER2 positivo con enfermedad residual tras la neoadyuvancia, usando un modelo de decisión que proyecta la supervivencia a 10 años. Consideraron también el riesgo de una complicación pulmonar grave asociada a uno de ellos.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Fan, J., Stenmark Tullberg, A., Kurian, A. W., Caswell-Jin, J. L., Dickerson, J. C., Alarid-Escudero, F.","url":"https://www.medrxiv.org/content/10.64898/2026.10.19.26365942v1?rss=1","imagen":"/hoy/portada/e7a4baed187642ae","tema":"salud","subtemas":["cáncer de mama","trastuzumab deruxtecan","toma de decisiones clínicas","efectos adversos","análisis de decisión"],"entidades":["FDA","medRxiv"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-22T00:00:00.000Z","indexTs":"2026-10-22T21:54:18.823Z","hash":"b3c2e7f0a0e3078479b20dd9fc6f2176cbcf99b338fc3945295224d8de844e38","tsa":{"time":"Oct 22 21:55:35 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"El nuevo fármaco redujo las recurrencias frente al anterior en pacientes de alto riesgo, pero conlleva un riesgo de daño pulmonar que puede ser fatal. El modelo sugiere que el beneficio podría no compensar ese riesgo en pacientes de menor riesgo, que la aprobación regulatoria incluye. Para una paciente de acá, la pregunta clave pasa a ser cuánto riesgo tiene ella antes de elegir el tratamiento.","quienFirma":"medRxiv (preprint)","confianza":"preprint","consulta":null},"sello":{"hash":"b3c2e7f0a0e3078479b20dd9fc6f2176cbcf99b338fc3945295224d8de844e38","sello":"00128e8d2f2097ae4cb9cc5a8ad7af3f9fc1507de49edd046b0bfe0f848d811a","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6575837,"aleatorio":"63461f681b6ee92f4c36de6febc3c3c4fe7c3906de725dea83aeab9ec81b1467","tiempo":"2026-10-22T21:55:30.000Z"},"nist":{"cadena":2,"pulso":1995118,"salida":"F0E0C41C949133434038AD3665131BA50B8741AD6763A98DA9C9F98A82572C39F0270A26E31EB0E30B2F4719DE6ED82AA401EE3E9EB6515A5780BD147A7BE091","tiempo":"2026-10-22T21:55:00.000Z"},"noAntes":"2026-10-22T21:55:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 22 21:55:35 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis","descripcion":"Background: For patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, escalating adjuvant treatment improves outcomes. In high-risk patients, DESTINY-Breast05 found that trastuzumab deruxtecan (T-DXd) reduced the 3-year risk of recurrence compared with trastuzumab emtansine (T-DM1). T-DXd also carries a risk of fatal interstitial lung disease (ILD). The US FDA approval for adjuvant T-DXd includes all patients with residual disease, including lower-risk patients not represented in the trial. We used decision modeling to project 10-year survival across recurrence-risk groups to aid in clinical decision-making. Methods: We modeled outcomes for 50-year-o","pubDate":"2026-10-22","url":"https://www.medrxiv.org/content/10.64898/2026.10.19.26365942v1?rss=1"},"indexado":"2026-10-22T21:54:18.823Z"}}